Time-dependent specificity of immunopathologic (C4d-CD68) and histologic criteria of antibody-mediated rejection for donor-specific antibodies and allograft dysfunction in heart transplantation

Transplantation

Volumn 99, Issue 3, 2015, Pages 586-593

  Yerly, Patrick ^a   Rotman, Samuel ^a   Nobile, Antoine ^a   Aubert, Vincent ^a   Tozzi, PierGiorgio ^a   Yarol, Nuray ^a   Vogt, Pierre ^a   Hullin, Roger ^a   Pascual, Manuel ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CD68 ANTIGEN; COMPLEMENT COMPONENT C4D; ANTIBODY; CD68 ANTIGEN, HUMAN; COMPLEMENT C4D; COMPLEMENT COMPONENT C4B; DIFFERENTIATION ANTIGEN; LEUKOCYTE ANTIGEN; PEPTIDE FRAGMENT;

ADULT; ANTIBODY MEDIATED REJECTION; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GRAFT DYSFUNCTION; HEART MUSCLE BIOPSY; HEART TRANSPLANTATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HUMORAL IMMUNITY; MALE; POSTOPERATIVE PERIOD; PREDICTIVE VALUE; PRIORITY JOURNAL; TIME; AGED; ALLOGRAFT; CHEMISTRY; DONOR; GRAFT REJECTION; HEART FAILURE; IMMUNOLOGY; MIDDLE AGED; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

AGED; ALLOGRAFTS; ANTIBODIES; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; COMPLEMENT C4B; FEMALE; GRAFT REJECTION; HEART FAILURE; HEART TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; POSTOPERATIVE PERIOD; SENSITIVITY AND SPECIFICITY; TIME FACTORS; TISSUE DONORS; TREATMENT OUTCOME;

EID: 84930518421     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0000000000000246     Document Type: Article

References (48)

1. Lund LH, Edwards LB, Kucheryavaya AY, International Society for Heart and Lung Transplantation. The Registry of the International Society for Heart and Lung Transplantation: thirtieth official adult heart transplant report-2013; focus theme: age. J Heart Lung Transplant 2013; 32: 951
2. Tan CD, Rodriguez ER,. Diagnosis of antibody-mediated rejection in cardiac transplantation: a call for standardization. Curr Opin Transplant 2010; 15: 769
3. Kfoury AG, Hammond ME,. Controversies in defining cardiac antibody-mediated rejection: need for updated criteria. J Heart Lung Transplant 2010; 29: 389
4. Kobashigawa J, Crespo-Leiro MG, Ensminger SM, Consensus Conference Participants. Report from a consensus conference on antibody-mediated rejection in heart transplantation. J Heart Lung Transplant 2011; 30: 252
5. Berry GJ, Angelini A, Burke MM, The ISHLT working formulation for pathologic diagnosis of antibody-mediated rejection in heart transplantation: evolution and current status (2005-2011). J Heart Lung Transplant 2011; 30: 601
6. Billingham ME, Cary NR, Hammond ME, A working formulation for the standardization and nomenclature in the diagnosis of heart and lung rejection: heart rejection study group. J Heart Transplant 1990; 9: 587
7. Bonnaud EN, Lewis NP, Masek MA, Reliability and usefulness of immunofluorescence in heart transplantation. J Heart Lung Transplant 1995; 14: 163
8. Behr TM, Feucht HE, Richter K, Detection of humoral rejection in human cardiac allografts by assessing the capillary deposition of complement fragment C4d in endomyocardial biopsies. J Heart Lung Transplant 1999; 18: 904
9. Crespo-Leiro MG, Veiga-Barreiro A, Domenech N, Humoral heart rejection (severe allograft dysfunction with no signs of cellular rejection or ischemia): incidence, management, and the value of C4d for diagnosis. Am J Transplant 2005; 5: 2560
10. Ollert MW, Kadlec JV, David K, Antibody-mediated complement activation on nucleated cells. A quantitative analysis of the individual reaction steps. J Immunol 1994; 153: 2213
11. Collins AB, Schneeberger EE, Pascual MA, Complement activation in acute humoral renal allograft rejection: diagnostic significance of C4d deposits in peritubular capillaries. J Am Soc Nephrol 1999; 10: 2208
12. Baldwin WM, Ota H, Rodriguez ER,. Complement in transplant rejection: diagnostic and mechanistic considerations. Springer Semin Immunopathol 2003; 25: 181
13. Rotman S, Collins A, Colvin R,. C4d deposition in allografts: current concepts and interpretation. Transplant Rev 2005; 19: 65
14. Böhmig GA, Exner M, Habicht A, Capillary C4d deposition in kidney allografts: a specific marker of alloantibody-dependent graft injury. J Am Soc Nephrol 2002; 13: 1091
15. Moll S, Pascual M,. Humoral rejection of organ allografts. Minireview. Am J Transplant 2005; 5: 2611
16. Stewart S, Winters GL, Fishbein MC, Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection. J Heart Lung Transplant 2005; 24: 1710
17. Reed EF, Demetris AJ, Hammond E, Acute antibody-mediated rejection of cardiac transplants. J Heart Lung Transplant 2006; 25: 153
18. Kittelson MM, Kobashigawa JA,. Antibody-mediated rejection. Curr Opin Organ Transplant 2012; 17: 551
19. Wu GW, Kobashigawa JA, Fishbein MC, Asymptomatic antibody-mediated rejection after heart transplantation predicts poor outcomes. J Heart Lung Transplant 2009; 28: 417
20. Kfoury AG, Hammond ME, Snow GL, Cardiovascular mortality among heart transplant recipients with asymptomatic antibody-mediated or stable mixed cellular and antibody-mediate rejection. J Heart Lung Transplant 2009; 28: 781
21. Sis B, Jhangri GS, Bunnag S, Endothelial gene expression in kidney transplants with alloantibody indicates antibody-mediated damage despite lack of C4d staining. Am J Transplant 2009; 9: 2312
22. Haas M,. Pathology of C4d-negative antibody-mediated rejection in renal allografts. Curr Opin Organ Transplant 2013; 18: 319
23. Berry GJ, Burke MM, Andersen C, The 2013 International Society of Heart and Lung Transplantation Working Formulation for the Standardization of nomenclature in the pathologic diagnosis of antibody-mediated rejection in heart transplantation. J Heart Lung Transplant 2013; 32: 1147
24. Tible M, Loupy A, Vernerey D, Pathologic classification of antibody-mediated rejection correlates with donor-specific antibodies and endothelial cell activation. J Heart Lung transplant 2013; 32: 769
25. Tan CD, Sokos GG, Pidwell DJ, Correlation of donor-specific antibodies, complement and its regulators with graft dysfunction in cardiac antibody-mediated rejection. Am J Transplant 2009; 9: 2075
26. Fedrigo M, Gambino A, Tona F, Can C4d immunostaining on endomyocardial biopsies be considered a prognostic biomarker in heart transplant recipients? Transplantation 2010; 90: 791
27. BGoes N, Urmson J, Ramassar V, Ischemic acute tubular necrosis induces an extensive local cytokine response: evidence for induction of interferon-c, transforming growth factorb-1, granulocyte-macrophage colony-stimulating factor, interleukin-2and interleukin-10. Transplant 1995; 59: 565
28. Shoskes DA, Parfrey NA, Halloran PF,. Increased major histocompatibility complex antigen expression in unilateral ischemic acute tubular-necrosis in the mouse. Transplant 1990; 49: 201
29. Halloran PF,. T Cell mediated rejection of kidney transplants: a personal viewpoint. Am J Transplant 2010; 10: 1126
30. Lones MA, Czer LS, Trento A, Clinical-pathologic features of humoral rejection in cardiac allografts: a study in 81 consecutive patients. J Heart Lung Transplant 1995; 14: 151
31. Baldwin WM 3rd, Samaniego-Picota M, Kasper EK, Complement deposition in early cardiac transplant biopsies is associated with ischemic injury and subsequent rejection episodes. Transplantation 1999; 68: 894
32. Baldwin WM III, Armstrong LP, Samaniego-Picota M, Antithymocyte globulin is associated with complement deposition in cardiac transplant biopsies. Hum Immunol 2004; 65: 1273
33. Kfoury AG, Stehlik J, Renlund DG, The impact of repetitive episodes of antibody-mediated or cellular rejection on cardiovascular mortality in cardiac transplant recipients: defining rejection patterns. J Heart Lung Transplant 2006; 25: 1277
34. Kfoury AG, Hammond ME, Snow GL, Early screening for antibody-mediated rejection in heart transplant recipients. J Heart Lung Transplant 2007; 26: 1264
35. Michaels PJ, Espejo ML, Kobashigawa JA, Humoral rejection in cardiac transplantation: risk factors, hemodynamic consequences and relationship to transplant coronary artery disease. J Heart Lung Transplant 2003; 22: 58
36. Nath DS, Tiriveedhi V, Basha HI, A role for antibodies to human leucocyte antigens, collagen-V and K-1-tubulin in antibody-mediated rejection and cardiac allograft vasculopathy. Transplant 2011; 91: 1036
37. Pettigrew GJ, Lovegrove E, Bradley JA, Indirect T cell allorecognition and alloantibody-mediated rejection of MHC class I-disparate heart grafts. J Immunol 1998; 161: 1292
38. Bharat A, Narayanan K, Street T, Early posttransplant inflammation promotes the development of alloimmunity and chronic human lung allograft rejection. Transplant 2007; 83: 150
39. Le Moine A, Goldman M, Abramowicz D,. Multiple pathways to allograft rejection. Transplant 2002; 73: 1373
40. Takemoto SK, Zeevi A, Feng S, National conference to assess antibody-mediated rejection in solid organ transplantation. Am J Transplant 2004; 4: 1033
41. Smith RN, Brousaides N, Grazette L, C4d deposition in cardiac allografts correlates with alloantibody. J Heart Lung Transplant 2005; 24: 1202
42. Rose ML, Smith JD,. Clinical relevance of complement-fixing antibodies in cardiac transplantation. Hum Immunol 2009; 70: 605
43. Zand MS, Vo T, Huggins J, Polyclonal rabbit antithymocyte globulin triggers B-cell and plasma cell apoptosis by multiple pathways. Transplant 2005; 79: 1507
44. Heidt S, Roelen DL, Eijsink C, Calcineurin inhibitors affect B cell antibody responses indirectly by interfering with T cell help. Clin Exp Immunol 2009; 159: 199
45. Hammond ME, Stehlik J, Snow G, and the Utah Transplant Affiliated Hospitals (UTAH) Cardiac Tansplant Program. Utility of histologic parameters in screening for antibody-mediated rejection of the cardiac allograft: a study of 3,170 biopsies. J Heart Lung Transplant 2005; 24: 2015
46. Yerly P, Mach F, Kalangos A, Monitoring and adjustment of immunosuppression after heart transplantation. Rev Med Suisse 2009; 5: 1214
47. Arias LF, Fernandez R, Fernandez D, C4D immunostaining in surveillance endomyocardial biopsies from well-functioning heart allografts. Transplant Proc 2010; 42: 1793
48. Aubert V, Venetz JP, Pantaleo G, Low levels of human leukocytes antigen donor-specific antibodies detected by solid phase assay before transplantation are frequently clinically irrelevant. Hum Immunol 2009; 700: 580